Johnson & Johnson (JNJ) Non-Current Assets (2009 - 2026)

Johnson & Johnson's (JNJ) quarterly Non-Current Assets came in at $141.7 billion in Q1 2026, up 16.05% year-on-year from $122.1 billion in Q1 2025, and down 1.3% quarter-over-quarter from $143.6 billion in Q4 2025.

Johnson & Johnson (JNJ) Non-Current Assets (2009 - 2026) Analysis & Trends

Johnson & Johnson has disclosed Non-Current Assets across 18 years of filings, most recently posting $141.7 billion for Q1 2026.

  • Non-Current Assets for Q1 2026 came in at $141.7 billion, up 16.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $562.4 billion (up 13.7% YoY), and the FY2025 annual result was $143.6 billion, up 15.6% from the prior year.
  • Non-Current Assets came in at $141.7 billion for Q1 2026 at Johnson & Johnson, down from $143.6 billion in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $143.6 billion in Q4 2025 to a low of $109.9 billion in Q4 2022.
  • The 5-year median for Non-Current Assets is $123.7 billion (2024), against an average of $125.3 billion.
  • Across the five-year window, Non-Current Assets dropped 13.64% in 2023 and grew 16.05% in 2026, its largest moves.
  • Johnson & Johnson's Non-Current Assets stood at $109.9 billion in 2022, then increased by 3.8% to $114.1 billion in 2023, then grew by 8.9% to $124.2 billion in 2024, then advanced by 15.6% to $143.6 billion in 2025, then fell by 1.3% to $141.7 billion in 2026.
  • The last three Non-Current Assets figures came in at $141.7 billion (Q1 2026), $143.6 billion (Q4 2025), and $138.2 billion (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn 60.81 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn 61.74 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn 141.72 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn 102.93 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn 125.00 Mn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn 61.03 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn 37.64 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn 165.18 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn 59.27 Bn
10 Novartis Ag 109.78 Bn 109.09 Bn - -

Historic Data

Download Data
DateValue
Mar 29, 2026 141.72 Bn
Dec 28, 2025 143.59 Bn
Sep 28, 2025 138.21 Bn
Jun 29, 2025 138.89 Bn
Mar 30, 2025 122.12 Bn
Dec 29, 2024 124.21 Bn
Sep 29, 2024 125.04 Bn
Jun 30, 2024 123.27 Bn
Mar 31, 2024 114.96 Bn
Dec 31, 2023 114.06 Bn
Oct 1, 2023 112.36 Bn
Jul 2, 2023 131.12 Bn
Apr 2, 2023 131.58 Bn
Jan 1, 2023 132.08 Bn
Oct 2, 2022 109.89 Bn
Jul 3, 2022 113.88 Bn
Apr 3, 2022 117.93 Bn
Jan 2, 2022 121.04 Bn
Oct 3, 2021 119.34 Bn
Jul 4, 2021 122.67 Bn